|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Löhr M: Is it possible to survive
pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 3:236–237.
2006.PubMed/NCBI
|
|
3
|
Omura N and Goggins M: Epigenetics and
epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol.
2:310–326. 2009.PubMed/NCBI
|
|
4
|
Tan W, Lu J, Huang M, et al: Anti-cancer
natural products isolated from Chinese medicinal herbs. Chin Med.
6:272011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao FH, Hu XH, Li W, et al: Oridonin
induces apoptosis and senescence in colorectal cancer cells by
increasing histone hyperacetylation and regulation of p16, p21, p27
and c-myc. BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera
S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via
activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAF-JNK
survival pathway in murine fibrosarcoma L929 cells. Arch Biochem
Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang J, Wu L, Tashiro S, Onodera S and
Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2
apoptosis through p53, MAPK, and mitochondrial signaling pathways.
J Pharmacol Sci. 107:370–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin S, Shen JN, Wang J, Huang G and Zhou
JG: Oridonin induced apoptosis through AKT and MAPKS signaling
pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li D, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin induced A431 cell apoptosis partially through
blockage of the RAS/RAF/ERK signal pathway. J Pharmacol Sci.
103:56–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu HZ, Yang YB, Xu XD, et al: Oridonin
induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa
cell line. Acta Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu YQ, Mu ZQ, You S, et al: Fas/FasL
signaling allows extracelluar-signal regulated kinase to regulate
cytochrome c release in oridonin-induced apoptotic U937 cells. Biol
Pharm Bull. 29:1873–1879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsieh TC, Wijeratne EK, Liang JY,
Gunatilaka AL and Wu JM: Differential control of growth, cell cycle
progression, and expression of NF-kappaB in human breast cancer
cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin,
diterpenoids from the Chinese herb Rabdosia rubescens.
Biochem Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ikezoe T, Chen SS, Tong XJ, et al:
Oridonin induces growth inhibition and apoptosis of a variety of
human cancer cells. Int J Oncol. 23:1187–1193. 2003.PubMed/NCBI
|
|
14
|
Bunz F, Dutriaux A, Lengauer C, et al:
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perfettini JL, Castedo M, Nardacci R, et
al: Essential role of p53 phosphorylation by p38 MAPK in apoptosis
induction by the HIV-1 envelope. J Exp Med. 201:279–289. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuribayashi K and El-Deiry WS: Regulation
of programmed cell death by the p53 pathway. Adv Exp Med Biol.
615:201–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuster JJ, Sanz-González SM, Moll UM and
Andrés V: Classic and novel roles of p53: prospects for anticancer
therapy. Trends Mol Med. 13:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burns TF, Fei P, Scata KA, et al:
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic
catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol.
23:5556–5571. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
20
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JT, Lehmann BD, Terrian DM, et al:
Targeting prostate cancer based on signal transduction and cell
cycle pathways. Cell Cycle. 7:1745–1762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCubrey JA, LaHair MM and Franklin RA:
Reactive oxygen species-induced activation of the MAP kinase
signaling pathways. Antioxid Redox Signal. 8:1775–1789. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kholodenko BN and Birtwistle MR:
Four-dimensional dynamics of MAPK information processing systems.
Wiley Interdiscip Rev Syst Biol Med. 1:28–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rodríguez-Berriguete G, Fraile B,
Martínez-Onsurbe P, et al: MAP kinases and prostate cancer. J
Signal Transduct. 2012:1691702012.PubMed/NCBI
|
|
25
|
Schaeffer HJ and Weber MJ:
Mitogen-activated protein kinases: specific messages from
ubiquitous messengers. Mol Cell Biol. 19:2435–2444. 1999.PubMed/NCBI
|
|
26
|
Zarubin T and Han J: Activation and
signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Whyte J, Bergin O, Bianchi A, McNally S
and Martin F: Key signalling nodes in mammary gland development and
cancer. Mitogen-activated protein kinase signalling in experimental
models of breast cancer progression and in mammary gland
development. Breast Cancer Res. 11:2092009. View Article : Google Scholar
|
|
28
|
Royuela M, Rodríguez-Berriguete G, Fraile
B and Paniagua R: TNF-α/IL-1/NF-κB transduction pathway in human
cancer prostate. Histol Histopathol. 23:1279–1290. 2008.
|
|
29
|
Thornton TM and Rincon M: Non-classical
p38 map kinase functions: cell cycle checkpoints and survival. Int
J Biol Sci. 5:44–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harris SL and Levine AJ: The p53 pathway:
positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu GS: The functional interactions between
the p53 and MAPK signaling pathways. Cancer Biol Ther. 3:156–161.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bulavin DV and Fornace AJ Jr: p38 MAP
kinase’s emerging role as a tumor suppressor. Adv Cancer Res.
92:95–118. 2004.
|
|
33
|
Degterev A, Boyce M and Yuan J: A decade
of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
|
